FDA review division director Badrul Chowdhury moved to AstraZeneca, the latest in a string of jumps to the pharmaceutical industry within the past year.

The panelists said the med's effects on the liver could be managed through labeling and education.

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

Christiana Care scientists edited DNA outside the cell for what they say is the first time.

The cash sets ex-Novartis executive Usman “Oz” Azam up to hustle Tmunity's pipeline of T cell-based immunotherapies through clinical development.

Novartis’ Jay Bradner questions whether the billions in cancer research funding within the industry is going in the right direction.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

Tsai took up the same position at Amgen 11 months ago but had his head turned by the digitally enabled pipeline Narasimhan is building at Novartis.